Switch theme
Sign up to access all valuation multiples
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
1992
5.5K+
LTM Revenue n/a
LTM EBITDA n/a
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tianjin Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Tianjin Pharma achieved revenue of $1.0B and an EBITDA of $378M.
Tianjin Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tianjin Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.0B | XXX | XXX | XXX |
| Gross Profit | $454M | $499M | XXX | XXX | XXX |
| Gross Margin | 40% | 50% | XXX | XXX | XXX |
| EBITDA | $174M | $378M | XXX | XXX | XXX |
| EBITDA Margin | 15% | 38% | XXX | XXX | XXX |
| Net Profit | $119M | $136M | XXX | XXX | XXX |
| Net Margin | 10% | 14% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Tianjin Pharma's stock price is CNY 27 (or $4).
Tianjin Pharma has current market cap of CNY 20.4B (or $2.8B), and EV of CNY 17.5B (or $2.4B).
See Tianjin Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.8B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Tianjin Pharma has market cap of $2.8B and EV of $2.4B.
Tianjin Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Tianjin Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Tianjin Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 6.4x | XXX | XXX | XXX |
| P/E | 9.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 21.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTianjin Pharma's NTM/LTM revenue growth is n/a
Tianjin Pharma's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Tianjin Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Tianjin Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Tianjin Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -11% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 118% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 36% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tianjin Pharma acquired XXX companies to date.
Last acquisition by Tianjin Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Tianjin Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Tianjin Pharma founded? | Tianjin Pharma was founded in 1992. |
| Where is Tianjin Pharma headquartered? | Tianjin Pharma is headquartered in China. |
| How many employees does Tianjin Pharma have? | As of today, Tianjin Pharma has 5.5K+ employees. |
| Is Tianjin Pharma publicy listed? | Yes, Tianjin Pharma is a public company listed on SHG. |
| What is the stock symbol of Tianjin Pharma? | Tianjin Pharma trades under 600329 ticker. |
| When did Tianjin Pharma go public? | Tianjin Pharma went public in 2001. |
| Who are competitors of Tianjin Pharma? | Similar companies to Tianjin Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tianjin Pharma? | Tianjin Pharma's current market cap is $2.8B |
| What is the current revenue growth of Tianjin Pharma? | Tianjin Pharma revenue growth between 2023 and 2024 was -11%. |
| Is Tianjin Pharma profitable? | Yes, Tianjin Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
